Furthermore, results presented in this work showing pro-tumorigenic functions for BMP9 in HCC cells acting to promote both anchorage dependent and independent growth and survival provide further evidences for the use of ALK1-fusion protein in HCC treatment considering that BMP9 withdrawal achieved by these drugs may target the liver cancer cell itself. This evidence concerns the gene GDF2 and liver cancer.